[Efficacy and survival analysis of DICE regimen for 97 patients with relapsed or refractory Non-Hodgkin's lymphoma].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Chinese Medical Association Country of Publication: China NLM ID: 8212398 Publication Model: Print Cited Medium: Print ISSN: 0253-2727 (Print) Linking ISSN: 02532727 NLM ISO Abbreviation: Zhonghua Xue Ye Xue Za Zhi Subsets: MEDLINE
    • Publication Information:
      Publication: Beijing : Chinese Medical Association
      Original Publication: Beijing : Zhongguo yi xue ke xue yuan.
    • Subject Terms:
      Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Lymphoma, Non-Hodgkin/*drug therapy; Cisplatin/administration & dosage ; Dexamethasone/administration & dosage ; Disease-Free Survival ; Etoposide/administration & dosage ; Female ; Humans ; Ifosfamide/administration & dosage ; Lymphoma, Large B-Cell, Diffuse ; Male ; Middle Aged ; Neutropenia ; Remission Induction ; Retrospective Studies ; Rituximab/administration & dosage ; Salvage Therapy ; Survival Analysis ; Thrombocytopenia
    • Abstract:
      Objective: To investigate the efficacy and survival of the DICE regimen (cisplatin, ifosfamide, etoposide, dexamethasone) for relapsed and refractory NHL. Methods: Clinical data of 97 relapsed and refractory NHL patients treated with DICE regimen in Peking University Cancer Hospital between Sep 1. 2008 and Dec 31. 2013 were retrospectively analyzed, and then we evaluate the efficacy and safety of DICE regimen. Results: ① There were 64 males and 33 females with a median age of 49 years. The most common pathological type was DLBCL (73.20%). There were 35 B-NHL patients used rituximab combined with DICE. Finally, a total of 26 patients underwent autologous stem cell transplantation (auto-HSCT) after the salvage chemotherapy. ② The overall response rate (ORR) was 47.42%, the complete response (CR) rate was 22.68%. The ORR of the relapsed/progressive group was higher than the refractory group [67.57% (25/37) vs 35.00% (21/60), χ 2 = 9.736, P =0.002]. ③The median follow-up of these 97 patients was 15.0 months (1.5-80.0 months). The expected median progression-free survival (PFS) and overall survival (OS) was 12.0 (95% CI 5.0-19.0) months, 26.0 (95% CI 6.0-45.9) months. ④There was no difference between the auto-HSCT group and no auto-HSCT group in the median OS [41.0 (95% CI 8.9-73.1) vs 22.0 (95% CI 8.5-35.5) months, P =0.361]. The patients who achieved CR and PR after DICE regimen had longer OS than those patients who in stable or progressive disease (56.0 vs 18.5 months, P <0.001). Patients who used DICE combined with rituximab had longer OS than patients who only used DICE regimen (51.5 vs 28.5 months, P =0.041). The multiple-factor analysis showed that the efficacy of DICE was an independent prognostic factor of OS [ HR =4.24 (95% CI 2.12-8.50), P <0.001 ]. ⑤ The major adverse events included neutropenia (84.54% ) , thrombocytopenia (41.24% ), anemia (68.04%), and nausea/vomiting (65.98%), 14 patients (14.43%) had liver function abnormality, 1 patient had acute renal function injury during the treatment period. There was no chemotherapy-related death occurred. Conclusion: The DICE regimen is effective in refractory and relapsed NHL, and DICE is safe and well-tolerated. The high response rate of DICE regimen may correlate with good prognosis. For the B-NHL patients who used DICE combined with rituximab had longer OS than those patients who used DICE regimen only.
    • References:
      J Clin Oncol. 1999 Dec;17(12):3776-85. (PMID: 10577849)
      Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):262-9. (PMID: 20709662)
      J Clin Oncol. 2013 Jan 1;31(1):88-94. (PMID: 23045577)
      Int J Cancer. 2004 Aug 10;111(1):131-7. (PMID: 15185354)
      J Natl Compr Canc Netw. 2014 Sep;12(9):1282-303. (PMID: 25190696)
      J Clin Oncol. 2010 Sep 20;28(27):4184-90. (PMID: 20660832)
      Semin Oncol. 1998 Aug;25(4):503-17. (PMID: 9728600)
      Zhonghua Xue Ye Xue Za Zhi. 2014 Apr;35(4):273-4. (PMID: 24759006)
      Leuk Lymphoma. 2005 Feb;46(2):197-206. (PMID: 15621802)
      Cancer Chemother Pharmacol. 1992;30(3):243-4. (PMID: 1628376)
      Eur J Haematol Suppl. 2001 Jul;64:41-5. (PMID: 11486401)
      Blood. 2004 May 15;103(10):3684-8. (PMID: 14739217)
      Ann Oncol. 2015 Aug;26(8):1766-71. (PMID: 26105599)
      Cancer. 1997 Nov 15;80(10):1989-96. (PMID: 9366303)
      Br J Haematol. 2014 Jul;166(1):77-83. (PMID: 24661044)
      Br J Cancer. 2001 Feb 2;84(3):303-7. (PMID: 11161392)
      J Clin Oncol. 2014 Sep 20;32(27):3059-68. (PMID: 25113753)
      Leuk Lymphoma. 1995 Jun;18(1-2):123-9. (PMID: 8580814)
      Semin Oncol. 2004 Feb;31(1 Suppl 2):12-6. (PMID: 15042529)
    • Accession Number:
      4F4X42SYQ6 (Rituximab)
      6PLQ3CP4P3 (Etoposide)
      7S5I7G3JQL (Dexamethasone)
      Q20Q21Q62J (Cisplatin)
      UM20QQM95Y (Ifosfamide)
    • Publication Date:
      Date Created: 20161011 Date Completed: 20181213 Latest Revision: 20201030
    • Publication Date:
      20240513
    • Accession Number:
      PMC7342104
    • Accession Number:
      10.3760/cma.j.issn.0253-2727.2016.09.012
    • Accession Number:
      27719723